Black Diamond Therapeutics
BDTX
87 hedge funds and large institutions have $103M invested in Black Diamond Therapeutics in 2024 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 35 increasing their positions, 16 reducing their positions, and 28 closing their positions.
119% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 16
1.56% less ownership
Funds ownership: 86.21% → 84.65% (-1.6%)
9% less funds holding
Funds holding: 96 → 87 (-9)
29% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 28
52% less capital invested
Capital invested by funds: $212M → $103M (-$109M)
77% less call options, than puts
Call options by funds: $38K | Put options by funds: $165K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$2.01M |
| 2 |
Renaissance Technologies
New York
|
+$1.86M |
| 3 |
VPC
Vestal Point Capital
New York
|
+$1.64M |
| 4 |
AAA
Affinity Asset Advisors
New York
|
+$1.6M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
ExodusPoint Capital Management
New York
|
-$3.8M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.03M |
| 3 |
OCA
Octagon Capital Advisors
New York
|
-$2.58M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$2.41M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$2.02M |
BDTX Hedge Fund Activity: Q4 2024 in Review
87 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Black Diamond Therapeutics (BDTX) for Q4 2024, worth a combined $103M — down 52% from $212M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of BDTX and 20 opened new positions — a net loss of 8 holders — while 16 trimmed existing stakes and 35 added.
The largest buyer was Tang Capital Management, adding an estimated $2.01M. The largest seller was ExodusPoint Capital Management, exiting entirely with an estimated $3.8M sold.
- 87 institutional investors held Black Diamond Therapeutics (BDTX) as of Q4 2024, down from 96 in Q3 2024.
- Funds reported $103M of Black Diamond Therapeutics stock for Q4 2024, down 52% quarter-over-quarter.
- 20 funds opened new Black Diamond Therapeutics positions in Q4 2024 and 28 closed out, a net change of -8 holders.
- The largest Black Diamond Therapeutics buyer in Q4 2024 was Tang Capital Management, an estimated $2.01M added.
- The largest Black Diamond Therapeutics seller in Q4 2024 was ExodusPoint Capital Management, an estimated $3.8M sold.
Based on aggregated 13F filings for Q4 2024.